General Information of DTT (ID: TTUST1O)

DTT Name Phosphodiesterase (PDE) DTT Info
Gene Name PDE

Molecule-Related Drug & Molecule List

Molecule-Related Drug List
Molecule Type:
DTT
DTP
DME
Drug Status:
Discontinued Drug(s)
Clinical Trial Drug(s)
Investigative Drug(s)
2 Clinical Trial Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
M-518101 DMZ6VD5 Plaque psoriasis EA90.0 Phase 3 [1]
NM-702 DMDJLY9 Angina pectoris BA40 Phase 3 [2]
------------------------------------------------------------------------------------
9 Discontinued Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
Piroximone DMQXJDM Cardiac failure BD10-BD13 Discontinued in Phase 3 [3]
AA-2379 DM78623 Inflammation 1A00-CA43.1 Discontinued in Phase 2 [4]
HN-10200 DMYJ1ZB Cardiac failure BD10-BD13 Discontinued in Phase 2 [5]
TIBENELAST DMYH2PU Asthma CA23 Discontinued in Phase 2 [6]
ALBIFYLLINE DMVBKLO Sepsis 1G40-1G41 Discontinued in Phase 1 [7]
BBB-022 DMITV4F Cerebrovascular ischaemia 8B1Z Terminated [8]
Isomazole DM4YJ2W Asthma CA23 Terminated [9]
JTT-608 DMZBNHC Diabetic complication 5A2Y Terminated [10]
Sch-45752 DME9Q3V Asthma CA23 Terminated [11]
------------------------------------------------------------------------------------
⏷ Show the Full List of 9 Discontinued Drug(s)
1 Investigative Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
DPN-205-734 DMSRUKQ Cardiac disease BA00-BE2Z Investigative [12]
------------------------------------------------------------------------------------
Molecule Interaction Atlas

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 The novel phosphodiesterase inhibitor NM-702 improves claudication-limited exercise performance in patients with peripheral arterial disease. J Am Coll Cardiol. 2006 Dec 19;48(12):2539-45.
3 Circulatory effects of the PDE-inhibitors piroximone and enoximone. Br J Clin Pharmacol. 1993 Oct;36(4):309-14.
4 Inhibitory effects of methyl 7-butyl-4,5,6,7-tetrahydro-3-methylamino-4,6-dioxo-5-propyl- 2H-pyrazolo[3,4-d]pyrimidine-2-carboxylate (AA-2379) on lysosomal enzyme and arachidonic acid release from rat polymorphonuclear leukocytes and its mode of action. Agents Actions. 1989 Nov;28(3-4):248-55.
5 HN-10200 causes endothelium-independent relaxations in isolated canine arteries. Cardiovasc Drugs Ther. 1992 Apr;6(2):159-65.
6 Effect of tibenelast (a phosphodiesterase inhibitor) and theophylline on isoproterenol-stimulated heart rate, cyclic AMP and norepinephrine levels. Pharmacology. 1993;46(3):142-7.
7 Enhanced tumor necrosis factor suppression and cyclic adenosine monophosphate accumulation by combination of phosphodiesterase inhibitors and prostanoids. Eur J Immunol. 1995 Jan;25(1):147-53.
8 Matrix metalloproteinase inhibition prevents oxidative stress-associated blood-brain barrier disruption after transient focal cerebral ischemia. J Cereb Blood Flow Metab. 2001 Dec;21(12):1393-400.
9 Effects of isomazole on force of contraction and phosphodiesterase isoenzymes I-IV in nonfailing and failing human hearts. J Cardiovasc Pharmacol. 1991 Sep;18(3):386-97.
10 JTT-608 controls blood glucose by enhancement of glucose-stimulated insulin secretion in normal and diabetes mellitus rats. Eur J Pharmacol. 1999 Feb 12;367(1):91-9.
11 SCH 45752--an inhibitor of calmodulin-sensitive cyclic nucleotide phosphodiesterase activity. J Antibiot (Tokyo). 1993 Feb;46(2):207-13.
12 Pharmacological actions of DPN 205-734, a novel cardiotonic agent. J Cardiovasc Pharmacol. 1988 Oct;12(4):451-60.